Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades - Wikidata - awgldk - TriplyDB

Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades

Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades

http://www.wikidata.org/entity/Q34132740

about

Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers "Liquid biopsy"-ctDNA detection with great potential and challenges Circulating glioma biomarkers Emerging methods for disease monitoring in malignant gliomas Blood-based biomarkers for malignant gliomas MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme--a systematic overview.Glioblastoma extracellular vesicles: reservoirs of potential biomarkers.Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma.MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma MGMT testing allows for personalised therapy in the temozolomide era.MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR Circulating nucleic acids in plasma and serum: diagnosis and prognosis in cancer Oncogenic extracellular vesicles in brain tumor progression miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.DNA methylation in repetitive elements and post-traumatic stress disorder: a case-control study of US military service members.Alu methylation serves as a biomarker for non-invasive diagnosis of glioma Testing two models describing how methylome-wide studies in blood are informative for psychiatric conditions.MBD-seq as a cost-effective approach for methylome-wide association studies: demonstration in 1500 case--control samples.A blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?MicroRNAs as regulators of neural stem cell-related pathways in glioblastoma multiforme.Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets.DNA methylation testing and marker validation using PCR: diagnostic applications.Cancer stem cells, microRNAs, and therapeutic strategies including natural products.Circulating biomarkers of CNS tumors: an update.Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.Brain metastasis: new opportunities to tackle therapeutic resistance.The continuing evolution: biology and treatment of brain tumors.Circulating biomarker panels for targeted therapy in brain tumors.A major role for microRNAs in glioblastoma cancer stem-like cells.Liquid biopsies in patients with diffuse glioma.Circulating biomarkers for gliomas.Emerging circulating biomarkers in glioblastoma: promises and challenges.Role of Circulating Cell-Free DNA in Cancers.Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.The "Liquid Biopsy": the Role of Circulating DNA and RNA in Central Nervous System Tumors.Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors.MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma.

P2860

Q21195201-D235564B-93BF-4541-A011-125BA0F0BCCC Q26779222-C22E8244-F7CE-4AC2-94AB-083C89A57F33 Q26830329-CBFDB327-8469-4F14-8974-7C27AE04FB28 Q27023823-9078FAF3-4FCF-4DAC-9EEE-869354F3E0D8 Q30625411-EF1414D0-147C-425A-86DE-B9C34CADEA01 Q34409620-9CEE23D3-49D1-4141-8180-F49794B05488 Q35122209-52AB99D6-CD78-47B7-BE5F-D9E616B968C1 Q35620669-08747DC9-456D-494E-BA9D-A9DAA2338751 Q35803479-EA112F95-DF75-4158-AB1D-C440C2AF960E Q35827916-A68D1455-B8D0-4B30-BA03-76475CEF5226 Q35850389-1476260F-D5E6-4250-897C-8B5A91FD8835 Q36117667-7F263E4F-AC37-4161-A61D-A372AE884ED2 Q36193774-99F3C876-6F12-485B-874D-7BBA3F9D9C2E Q36608190-A26BD39A-6D92-4F3B-A667-9507CC9A3ADA Q37039354-1676252C-0022-4FED-8E48-C195C94C1067 Q37225239-2F5F2392-23C0-49FB-A9EC-EC4EF01882EB Q37259389-6B1D89E6-667F-483E-89C1-158A957DAA8A Q37295593-7EB4E77C-F385-4A07-9DF9-9552A852DAC5 Q37524743-3CF12D1D-CFC5-4124-BB74-1225F48EE3CA Q37581443-782CDDF5-CD4D-4FAF-884F-11883E386862 Q37707565-DF1D4C2B-84DE-4BF3-86FB-A52E1BE8CE38 Q37797464-812F84E9-A48F-44F0-992C-26BE296882A1 Q37897499-CC513948-DF37-4838-80CD-13ED6BD8AF37 Q37937061-78F1075D-177E-4E4C-B70E-699312D9ECE9 Q37963517-AD015E1D-608C-4745-AF2D-01A57F07FA09 Q38023238-EDD0DC13-0851-4685-8856-AC7D78B96E38 Q38095109-A2FA97F9-86B8-444F-946A-E0ACA34DBA81 Q38152782-9BD8319D-70B9-49B1-AF67-7E6CE52811DA Q38222247-F96A5CDA-45AA-4161-9216-7B4E667AFC3D Q38230516-B6743ABC-6EDE-4118-83ED-D04B06B376CC Q38252948-33DFFD40-EE8C-4714-A3D4-506FABA3F626 Q38356196-B6FF8EC9-CEB5-48C4-AAA1-20FA55E76C69 Q38365590-3470EAFA-A9FE-40B3-BC94-3768B2B14E8F Q38586617-43464DDC-F2AF-421E-8BF2-618D83A8CC34 Q38591062-884AF3A4-9021-457D-9A51-B67550E29B2A Q38591963-70DC74D3-CF65-454F-9EFE-B0329F3A76AA Q38699764-C4E7E1F3-A833-4F66-87BD-74C532CED0C0 Q38720700-3DB83F3B-E2F4-4998-A96B-B70A9CB23250 Q38777383-748F0E0F-44C6-4625-BCDB-67B32875EE7D Q38885288-B6DB6225-ECC3-49C8-88C2-7948BE9D01B1

P2860

Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades

http://www.wikidata.org/entity/Q34132740

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Serum DNA can define tumor-spe ...... s in gliomas of various grades

@ast

Serum DNA can define tumor-spe ...... s in gliomas of various grades

@en

Serum DNA can define tumor-spe ...... s in gliomas of various grades

@nl

type

label

Serum DNA can define tumor-spe ...... s in gliomas of various grades

@ast

Serum DNA can define tumor-spe ...... s in gliomas of various grades

@en

Serum DNA can define tumor-spe ...... s in gliomas of various grades

@nl

prefLabel

Serum DNA can define tumor-spe ...... s in gliomas of various grades

@ast

Serum DNA can define tumor-spe ...... s in gliomas of various grades

@en

Serum DNA can define tumor-spe ...... s in gliomas of various grades

@nl

P1433

Q34132740-5D62894A-09AA-443E-9F7E-E8BE25ADF8F2

P1476

Q34132740-9492F67B-96F1-42BD-8E11-67ED4A451230

P2093

Q34132740-462A6E06-C518-413C-A06C-761CAB55F53C

Q34132740-7A40720C-9040-43FD-BCF3-9F9D10079637

Q34132740-824FC6EC-B498-495D-AF16-C997112E9411

Q34132740-AF831A75-47B1-4B55-B7BA-353CAB43306D

Q34132740-CC4C1930-742E-4208-A5E9-61E099F81654

P2860

Q34132740-1D35AB57-9E24-493C-8CB1-461FF14FC1EE

Q34132740-20ED8E25-5E89-4D92-B920-71CDA02BA1AE

Q34132740-2166BFBF-7ADE-4C22-A11D-D4E2B5C718E3

Q34132740-28DF9587-86FD-41A2-B743-53C8AF8B1159

Q34132740-2ACF5E79-BB89-4018-97A7-0EA9ED208F95

Q34132740-2B2FBDD1-0482-4516-8D96-7C5757819E94

Q34132740-2B4CFF3C-EB46-44C9-B645-6D8A9F5CAD8B

Q34132740-2F020C31-F780-459A-9076-9D70BA484BC3

Q34132740-3623C686-EB07-474D-B498-5B3594D4FB72

Q34132740-42D6462B-7AF4-4A8A-89F3-B0353A5DF391

P304

Q34132740-91EC9F2C-FB07-496D-A2CC-7C9080CC7FEB

P31

Q34132740-A3D220A8-0D78-4B11-B353-756FE02CCFB7

P356

Q34132740-C373E0B8-4AFF-432B-870A-233E4B814831

P433

Q34132740-4D6015E1-AA06-4232-884B-3160DEA5D76F

P478

Q34132740-982AA848-A2C8-4CA2-9323-3354B205BB94

P577

Q34132740-F3E31631-952A-4D4F-842D-9FCCCE365E79

P5875

Q34132740-BFCE8C8A-93D4-42C6-AD49-35FC4B0590CD

P698

Q34132740-54B38631-C192-4C48-9B38-29927076FCE3

P932

Q34132740-F8BF25E2-A352-4F4A-B0D3-4367623925F7

P356

P1433

P1476

Serum DNA can define tumor-spe ...... s in gliomas of various grades

@en

P2093

Bracha Zelikovitch

http://www.w3.org/2001/XMLSchema#string

Edna Shalom

http://www.w3.org/2001/XMLSchema#string

Iris Lavon

http://www.w3.org/2001/XMLSchema#string

Miri Refael

http://www.w3.org/2001/XMLSchema#string

Tali Siegal

http://www.w3.org/2001/XMLSchema#string

P2860

Bisulfite genomic sequencing: systematic investigation of critical experimental parameters

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Circulating mutant DNA to assess tumor dynamics

Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma.

Downregulation of RUNX3 and TES by hypermethylation in glioblastoma.

Oligodendroglioma.

Detection and quantification of mutations in the plasma of patients with colorectal tumors.

Neoplastic characteristics of the DNA found in the plasma of cancer patients.

Prediction of breast tumor progression by integrity of free circulating DNA in serum.

P304

173-180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOP041

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41424794

http://www.w3.org/2001/XMLSchema#string

P698

20150384

http://www.w3.org/2001/XMLSchema#string

P932

2940579

http://www.w3.org/2001/XMLSchema#string